Immunology/Inflammation
Immunology/Inflammation(免疫及炎症)
The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.
Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].
BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].
Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.
Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].
References
[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.
[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.
[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.
[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.
[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.
[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.
[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.
[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.
- 5-Lipoxygenase(11)
- Papain(1)
- PGDS(1)
- PGE synthase(24)
- SIKs(12)
- IκB/IKK(67)
- AP-1(6)
- KEAP1-Nrf2(65)
- NOD1(1)
- TLR(140)
- NF-κB(241)
- Interleukin Related(171)
- 15-lipoxygenase(2)
- Others(63)
- Aryl Hydrocarbon Receptor(36)
- CD73(14)
- Complement System(58)
- Galectin(12)
- IFNAR(25)
- NO Synthase(77)
- NOD-like Receptor (NLR)(51)
- STING(110)
- Reactive Oxygen Species(465)
- Apoptosis(802)
- FKBP(20)
- eNOS(5)
- iNOS(29)
- nNOS(20)
- Glutathione(57)
- Adaptive Immunity(222)
- Allergy(130)
- Arthritis(34)
- Autoimmunity(190)
- Gastric Disease(101)
- Immunosuppressants(39)
- Immunotherapeutics(5)
- Innate Immunity(593)
- Pulmonary Diseases(119)
- Reactive Nitrogen Species(55)
- Reactive Sulfur Species(28)
- Specialized Pro-Resolving Mediators(50)
- Cyclic GMP-AMP Synthase(2)
- BCL6(3)
- CD20(3)
- CD22
- CD28(1)
- FAP(7)
- PSMA(7)
- Nuclear Factor of activated T Cells (NFAT)(1)
- Glycoprotein VI(1)
- Tim3(2)
- Hapten(1)
- Nectin-4(2)
Immunology/Inflammation 相关产品(4245)
- GC74486LexatumumabCAS: 845816-02-6纯度: >96.00%
Lexatumumab(HGS-ETR 2)是一种人激动性TRAIL受体2(TRAIL-R2、DR5、APO-2)IgG4κ型单克隆抗体。
- GC74491TucotuzumabCAS: 339986-90-2纯度: >95.00%
Tucotuzumab (Anti-EPCAM Recombinant Antibody)是一种针对人上皮细胞粘附分子(EpCAM)的抗原特异性IgG1单克隆抗体。
- GC74499TalacotuzumabCAS: 1826831-79-1纯度: >98.00%
Talacotuzumab(JNJ 56022473;CSL 362)是一种IgG1型完全人源化的CD123中和单克隆抗体,含有修饰的Fc结构。
- GC74501AdebrelimabCAS: 2247114-85-6纯度: >97.00%
Adebrelimab(SHR-1316)是一种人源化IgG4单克隆PD-L1(PD-1/PD-L1)抗体。
- GC74518BrazikumabCAS: 1610353-18-8纯度: >95.00%
Brazikumab (AMG 139)是一种人IgG2单克隆抗体,选择性结合IL-23的p19亚基,对人IL-23的KD为0.138 nM。
- GC74552GefurulimabCAS: 2456407-94-4纯度: >97.00%
Gefurulimab(ALXN-1720)是一种来源于人的针对补体C5和白蛋白的双特异性抗体,可结合C5并阻断其激活。
- GC74559InbakiceptCAS: 2135939-52-3纯度: >98.00%
Inbakicept是一种二聚体人IL-15受体α (IL-15 Ra)寿司结构域/人IgG1 Fc融合蛋白,是一种IL-15超级激动剂复合物。
- GC74605Simlukafusp alfaCAS: 1776942-10-9纯度: >95.00%
Simlukafusp alfa(FAP-IL2v)是一种免疫细胞因子,包含抗成纤维细胞活化蛋白α(FAPα)的抗体和仅结合IL-2Rβγ的IL-2变体。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC74477 | Tigatuzumab | 918127-53-4 | >95.00% | |
Tigatuzumab(CS-1008)是一种靶向死亡受体5(DR5)的人源化IgG1单克隆抗体。 | ||||
| GC74482 | Drozitumab | 912628-39-8 | >99.00% | |
Drozitumab(PRO 95780)是一种结合死亡受体DR5的人激动性单克隆抗体。 | ||||
| GC74483 | Galiximab | 357613-77-5 | >99.00% | |
Galiximab (IDEC 114)是一种靶向CD80抗原并阻断CD80 - cd28结合的免疫球蛋白G1 (IgG1) lambda单克隆抗体。 | ||||
| GC74486 | Lexatumumab | 845816-02-6 | >96.00% | |
Lexatumumab(HGS-ETR 2)是一种人激动性TRAIL受体2(TRAIL-R2、DR5、APO-2)IgG4κ型单克隆抗体。 | ||||
| GC74488 | Sirukumab | 1194585-53-9 | >95.00% | |
Sirukumab(CNTO-136)是一种人源化单克隆抗IL6(白细胞介素相关)IgG1κ抗体。 | ||||
| GC74490 | Tositumomab | 192391-48-3 | 不显示 | |
Tositumomab是一种针对CD20抗原的鼠IgG2aλ单克隆抗体,该抗原存在于正常和恶性B淋巴细胞的表面。 | ||||
| GC74491 | Tucotuzumab | 339986-90-2 | >95.00% | |
Tucotuzumab (Anti-EPCAM Recombinant Antibody)是一种针对人上皮细胞粘附分子(EpCAM)的抗原特异性IgG1单克隆抗体。 | ||||
| GC74499 | Talacotuzumab | 1826831-79-1 | >98.00% | |
Talacotuzumab(JNJ 56022473;CSL 362)是一种IgG1型完全人源化的CD123中和单克隆抗体,含有修饰的Fc结构。 | ||||
| GC74501 | Adebrelimab | 2247114-85-6 | >97.00% | |
Adebrelimab(SHR-1316)是一种人源化IgG4单克隆PD-L1(PD-1/PD-L1)抗体。 | ||||
| GC74515 | Benufutamab | 2109730-69-8 | >98.00% | |
Benufutamab(GEN1029)是一种死亡受体5(DR5)特异性激动抗体。 | ||||
| GC74518 | Brazikumab | 1610353-18-8 | >95.00% | |
Brazikumab (AMG 139)是一种人IgG2单克隆抗体,选择性结合IL-23的p19亚基,对人IL-23的KD为0.138 nM。 | ||||
| GC74523 | Xeligekimab | 2382921-73-3 | >95.00% | |
Xeligekimab (GR 1501)是一种抗人白细胞介素17A (IL-17A)人源化单克隆抗体。 | ||||
| GC74528 | Urabrelimab | 2249722-58-3 | >98.00% | |
Urabrelimab(SRF231)是一种阻断CD47-SIRP相互作用的全人源性抗CD47单克隆抗体。 | ||||
| GC74538 | Sotevtamab | 2411526-47-9 | >99.00% | |
Sotevtamab (16B5)是一种人源IgG2抗聚簇素单克隆抗体(mAb)。 | ||||
| GC74552 | Gefurulimab | 2456407-94-4 | >97.00% | |
Gefurulimab(ALXN-1720)是一种来源于人的针对补体C5和白蛋白的双特异性抗体,可结合C5并阻断其激活。 | ||||
| GC74559 | Inbakicept | 2135939-52-3 | >98.00% | |
Inbakicept是一种二聚体人IL-15受体α (IL-15 Ra)寿司结构域/人IgG1 Fc融合蛋白,是一种IL-15超级激动剂复合物。 | ||||
| GC74566 | Keliximab | 174722-30-6 | >98.00% | |
Keliximab (SB-210396)是一种嵌合人/猕猴IgG1抗CD4单克隆抗体,对可溶性CD4的Ki值为1.0 nM。 | ||||
| GC74571 | Ligufalimab | 2428381-55-7 | >98.00% | |
Ligufalimab(AK 117)是一种人源化IgG4抗CD47单克隆抗体。 | ||||
| GC74572 | Lilotomab | 1453362-55-4 | >98.00% | |
Lilotomab(0-40µg/mL;12 d)降低DOHH2和Ramos细胞的克隆性存活。 | ||||
| GC74585 | Obexelimab | 1690307-05-1 | >95.00% | |
Obexelimab(XmAb5871)是一种人源化抗CD19抗体。 | ||||
| GC74588 | Plamotamab | 2138442-31-4 | >99.00% | |
Plamotamab(XmAb-13676)是一种结合CD3和CD20的人双特异性抗体(bsAb)。 | ||||
| GC74590 | Pozelimab | 2096328-94-6 | >99.00% | |
Pozelimab(REGN3918)是一种全人IgG4抗C5单克隆抗体。 | ||||
| GC74599 | Cobolimab | 2022215-65-0 | >98.00% | |
Cobolimab(TSR-022)是一种抗TIM-3单克隆抗体。 | ||||
| GC74605 | Simlukafusp alfa | 1776942-10-9 | >95.00% | |
Simlukafusp alfa(FAP-IL2v)是一种免疫细胞因子,包含抗成纤维细胞活化蛋白α(FAPα)的抗体和仅结合IL-2Rβγ的IL-2变体。 | ||||
